HOME >> MEDICINE >> NEWS
Anti-coagulation drugs found to have different effects in diabetics after heart attack

CHICAGO -- In a sub-analysis of data from an earlier trial comparing the ability of three agents used to restore blood flow to patients soon after heart attacks, researchers have found that drugs used to prevent blood coagulation appear to have different effects in heart patients with diabetes.

These findings, coupled with an assessment of ease of administration and cost compared to other drugs, leads researchers from Duke University Medical Center to recommend the drug enoxaparin, which is a low-molecular weight heparin, for acute heart attack patients with diabetes.

The Duke team reported the results of its analysis today (Nov. 20, 2002) at the 75th annual scientific session of the American Heart Association.

When heart attack patients are rushed to the emergency room, physicians immediately try to restore blood flow to the heart, usually by giving medications that dissolve clots in the coronary arteries. Since no one drug has been totally effective on its own in opening clogged arteries and keeping them open, researchers have tried different combinations of agents.

Thus was born the ASSENT-3 trial, the results of which were published in August 2001 in the journal Lancet. The trial enrolled 6,116 patients and documented the combined rates of death, recurrent heart attack or refractory chest pain. They then used this composite endpoint to measure the effectiveness of three different combinations of drugs.

All patients entered the hospital within six hours of a heart attack and were given varying doses of tenecteplase, a genetically altered version of the well-known clot-buster t-PA, which quickly dissolves the blood clot. Patients were then randomized to receive additional agents intended to keep the vessels clear: the blood-thinner enoxaparin; the blood-thinner unfractionated heparin plus abciximab (an agent that keeps platelets in the blood from clumping); or unfractionated heparin alone.

ASSENT-3 found that both th
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Nov-2002


Page: 1 2 3

Related medicine news :

1. UW research shows risk factors for relapse among health care professionals who abuse drugs
2. New studies show mixed results on epilepsy drugs and birth defects
3. Newly discovered pathway might help in design of cancer drugs
4. Study examines consequences of Thailands war on drugs
5. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
6. Three anti-platelet drugs used in combination are safe
7. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
8. Clot-busting drugs may help detect potentially deadly leg clots
9. Herb used to treat diabetes works like modern-day prescription drugs, study suggests
10. Penn study shows how next-generation diabetic drugs could work more selectively
11. Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

Post Your Comments:
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and amputation , AUGUST 3, 2015 – Since winning a South by Southwest® ... Not Impossible – an organization whose mission is to develop technology for the ...
(Date:8/3/2015)... ... 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and ... Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker ... the Company’s presentation may be accessed via the investor relations section of the Company’s ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... MOUNT PROSPECT, Ill. , July 31, 2015 ... of Pharmacy ® (NABP ® ) issued ... charged with ensuring that action is taken against ... the Internet Drug Outlet Identification Program ... 2015 , thousands of websites ...
Breaking Medicine Technology:Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
Cached News: